Analysts Set Expectations for Sutro Biopharma Q1 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – Stock analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Sutro Biopharma in a note issued to investors on Tuesday, March 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.53) for the quarter, down from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2026 earnings at ($2.58) EPS, Q3 2026 earnings at ($2.59) EPS, Q4 2026 earnings at ($2.62) EPS, FY2026 earnings at ($10.32) EPS, FY2027 earnings at ($8.27) EPS, FY2028 earnings at ($8.06) EPS and FY2029 earnings at ($5.63) EPS.

Other research analysts have also issued reports about the stock. Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Wells Fargo & Company raised Sutro Biopharma from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $8.00 to $27.00 in a report on Tuesday. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Finally, Wedbush reissued a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Sutro Biopharma presently has an average rating of “Moderate Buy” and an average target price of $37.29.

Sutro Biopharma Stock Performance

Sutro Biopharma stock opened at $24.43 on Thursday. Sutro Biopharma has a one year low of $5.23 and a one year high of $26.54. The company has a 50-day simple moving average of $19.06 and a 200-day simple moving average of $12.94. The firm has a market capitalization of $207.90 million, a P/E ratio of -0.94 and a beta of 1.47.

Hedge Funds Weigh In On Sutro Biopharma

Several large investors have recently bought and sold shares of STRO. Invesco Ltd. lifted its stake in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after acquiring an additional 53,390 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after acquiring an additional 1,206,330 shares in the last quarter. Strs Ohio acquired a new position in shares of Sutro Biopharma during the first quarter valued at approximately $99,000. Marshall Wace LLP bought a new stake in Sutro Biopharma during the second quarter worth approximately $166,000. Finally, Cerity Partners LLC raised its holdings in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55, signaling strong upside from current levels; that lift to a much higher PT supports bullish investor sentiment. Deutsche Bank Raises Price Target to $55
• Positive Sentiment: Wells Fargo upgraded Sutro to “Overweight,” an endorsement that can attract institutional buying. Wells Fargo Upgrades Sutro Biopharma to Overweight
• Positive Sentiment: Truist moved the stock to “strong-buy” (reported via Zacks), another supportive vote of confidence from the sell side. Truist Upgrades to Strong-Buy (Zacks)
• Neutral Sentiment: HC Wainwright published commentary on Sutro’s FY2030 outlook — the note offers long‑range modeling context but is not a straightforward buy/sell trigger by itself. HC Wainwright Comments on Sutro FY2030 Earnings
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts (Q1–Q4 FY2026 and FY2026–FY2029), moving projected losses much deeper while keeping a Buy rating and a $28 target. Those sizable downward revisions increase short‑term downside risk and help explain selling pressure despite upgrades. HC Wainwright Lowers Multiple EPS Estimates (MarketBeat)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.